Consolidated Statement Of Comprehensive Income

ONO PHARMACEUTICAL CO., LTD. - Filing #7595379

Concept 2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2022-04-01 to
2022-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
Consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
29,477,000,000 JPY
29,477,000,000 JPY
29,528,000,000 JPY
51,000,000 JPY
34,000,000 JPY
24,074,000,000 JPY
24,074,000,000 JPY
24,108,000,000 JPY
Other comprehensive income
Items that will not be reclassified to profit or loss
Remeasurements of defined benefit plans
-10,000,000 JPY
210,000,000 JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income
-845,000,000 JPY
-1,684,000,000 JPY
Total of items that will not be reclassified to profit or loss
-850,000,000 JPY
-1,471,000,000 JPY
Items that may be reclassified to profit or loss
Exchange differences on translation of foreign operations
875,000,000 JPY
51,000,000 JPY
Effective portion of cash flow hedges
144,000,000 JPY
9,000,000 JPY
Total of items that may be reclassified to profit or loss
1,019,000,000 JPY
60,000,000 JPY
Other comprehensive income
173,000,000 JPY
173,000,000 JPY
169,000,000 JPY
-4,000,000 JPY
-1,412,000,000 JPY
1,000,000 JPY
-1,412,000,000 JPY
-1,411,000,000 JPY
Comprehensive income
173,000,000 JPY
29,650,000,000 JPY
29,477,000,000 JPY
29,697,000,000 JPY
JPY
47,000,000 JPY
JPY
JPY
-1,412,000,000 JPY
34,000,000 JPY
JPY
22,662,000,000 JPY
24,074,000,000 JPY
JPY
JPY
22,696,000,000 JPY
Comprehensive income attributable to
Owners of parent
29,650,000,000 JPY
22,662,000,000 JPY
Non-controlling interests
47,000,000 JPY
34,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.